Enterprise Products Partners (EPD): High-Yield Stability Meets Measured Growth in 2026

Enterprise Products Partners L.P. (NYSE: EPD), one of the largest midstream energy operators in North America, continues to attract income-focused investors in 2026 with a combination of steady cash flows, a strong dividend track record, and modest but reliable growth prospects.

Power plant with cooling towers and electrical substation with transmission lines at sunset
A power plant surrounded by transmission towers during a vibrant sunset

Stock Performance and Current Price

As of late April 2026, EPD shares are trading in the mid-to-high $30 range (approximately $36–$38 per unit), slightly below analyst consensus targets near $39.50.

The stock has demonstrated resilience this year, gaining over 20% year-to-date amid improving fundamentals and renewed investor interest in energy infrastructure assets.

Despite some short-term volatility and minor earnings misses, the broader trend remains constructive, supported by stable demand for oil, natural gas liquids (NGLs), and export services.

Dividend Profile: A Core Income Play

Enterprise Products Partners remains a standout in the income investing space:

  • Annual distribution: ~$2.20 per unit
  • Quarterly payout: $0.55
  • Dividend yield: ~5.8%–6.0%
  • Dividend growth streak: 28 consecutive years

The company recently reaffirmed its quarterly distribution for 2026, reflecting a ~2–3% year-over-year increase, consistent with its conservative capital return strategy.

Unlike high-growth equities, EPD prioritizes distribution stability and coverage, maintaining payout ratios supported by strong operating cash flow.

Financial Strength and Operational Momentum

Recent earnings and operational data highlight steady performance:

  • Q1 2026 EBITDA: ~$2.7 billion
  • Operating income growth: +8%
  • Revenue beat expectations despite EPS miss

Enterprise’s diversified asset base spanning pipelines, storage, processing, and export terminals continues to generate predictable fee-based income, insulating the business from commodity price volatility.

Growth Outlook: Moderate in 2026, Stronger Beyond

Looking ahead, analysts expect measured growth in 2026, with stronger acceleration into 2027:

  • 2026 outlook: Transitional year with stable cash flow
  • 2027+: Potential double-digit EBITDA and cash flow growth as new projects come online
  • Capital projects pipeline: ~$6 billion in infrastructure investments

Wall Street forecasts also indicate gradual earnings expansion:

  • 2026 estimated earnings: ~$6.1B
  • 2027 estimated earnings: ~$6.8B

This positions EPD as a “slow compounder” rather than a high-growth equity ideal for long-term income portfolios.

Key Investment Highlights

MetricValue / Insight
Current Stock Price~$36–$38
Dividend Yield~5.8%–6.0%
Annual Distribution~$2.20
Dividend Growth Streak28 years
2026 Stock Performance~+20% YTD
EBITDA (Q1 2026)~$2.7B
Growth OutlookModerate 2026, stronger 2027+
Analyst Target~$39.50

Investment Thesis

Enterprise Products Partners continues to deliver on its core value proposition: reliable income with low volatility and gradual capital appreciation.

Bull Case:

  • Durable, fee-based midstream business model
  • Strong balance sheet and distribution coverage
  • High yield relative to broader equity markets
  • Visible long-term growth pipeline

Bear Case:

  • Limited near-term upside due to mature asset base
  • Slower dividend growth compared to peers
  • Sensitivity to energy demand cycles and interest rates

Bottom Line

For 2026, Enterprise Products Partners is best viewed as a defensive income vehicle rather than a growth stock. Investors seeking consistent yield and stability in uncertain markets may find EPD particularly attractive, while those pursuing aggressive capital gains may look elsewhere.

With a near-6% yield, a decades-long dividend track record, and improving long-term growth catalysts, EPD remains a cornerstone holding in the midstream energy sector.

Disclosure Statement

Disclosure: The author currently holds a position in Enterprise Products Partners L.P. (NYSE: EPD). This article is for informational purposes only and should not be considered financial advice. Investors should conduct their own due diligence or consult a licensed financial professional before making investment decisions.


References (APA Format)

Yahoo Finance. (2026). Enterprise Products Partners L.P. (EPD) stock price, news, and analysis. Retrieved May 2, 2026, from https://finance.yahoo.com/

MarketBeat. (2026). Enterprise Products Partners dividend history and yield. Retrieved May 2, 2026, from https://www.marketbeat.com/

Simply Wall St. (2026). Enterprise Products Partners distribution updates and analysis. Retrieved May 2, 2026, from https://simplywall.st/

Intellectia. (2026). Enterprise Products Partners starts 2026 strong with stock gains. Retrieved May 2, 2026, from https://intellectia.ai/

The Motley Fool. (2026). Energy dividend stocks outlook and analysis. Retrieved May 2, 2026, from https://www.fool.com/

Seeking Alpha. (2026). Enterprise Products Partners: Growth outlook and capital projects. Retrieved May 2, 2026, from https://seekingalpha.com/

WallStreetZen. (2026). EPD stock forecast and earnings projections. Retrieved May 2, 2026, from https://www.wallstreetzen.com/

A Brighter Outlook (Despite Skepticism): Could OSCR Reach $40 by Christmas 2025?

1. Highly Bullish Long-Term Forecasts

Some quantitative models project a steep upward trajectory. One forecasting service estimates an average December 2025 price of $34.67, with a low of $32.18 and a high of $35.72—implying over 100% upside from current levels (StockScan). If investor sentiment catches up with this model, the stock could indeed flirt with $40 before year-end.

2. Financing Strength and Cash Position

As of March 31, 2025, Oscar Health reported a fortified balance sheet: $4.86 billion in cash, equivalents, and investments, up from $3.97 billion at the end of 2024. Total assets rose 21% YoY, while operating cash flow increased 38% (Michael Burry’s Insights). This cash cushion gives Oscar flexibility to invest in growth, navigate regulatory headwinds, and drive further value.

3. Strategic Expansion Through New Partnerships

Oscar’s deal with Hy-Vee to launch “Hy-Vee Health with Oscar” in Des Moines, covering about 400,000 employees in the individual marketplace starting Jan 1, 2026, signals a bold move into employer-backed coverage. The ICHRA model aims to save businesses 20–30% and deliver substantial cost-savings to employees-this could create significant scale and margin tailwinds (Benzinga).

4. Accelerating Revenue Growth

While Q2 revenue of $2.86 billion fell slightly short of the $2.91 billion estimate, it still marked a 29% increase YoY. The company reaffirmed its full-year 2025 revenue guidance at $12–12.2 billion (versus Wall Street’s $11.32 billion estimate), underscoring underlying growth momentum (BenzingaYahoo FinanceStockAnalysis).

5. Valuation Appears Undervalued for Growth Potential

Oscar trades at over 101x forward EV/EBITDA, a lofty multiple—but some analysts argue this valuation is justified by its “quality characteristics” and disruptive business model (StockStory). Others see it as deeply undervalued despite near-term uncertainty tied to ACA policy risks (Seeking Alpha+1).


Why Analysts Are Still Cautious

  • Low Analyst Price Targets: Consensus 12-month forecasts range between $8 and $14, with averages clustered around $11–$12—well below the $40 mark (ZacksThe Wall Street JournalPriceTargetsInvesting.com).
  • Skeptical Market Sentiment: Many brokerages hold “Sell,” “Hold,” or “Neutral” ratings. Notably, Piper Sandler cut its target from $14 to $13, citing uncertainties around risk adjustments and path to profitability (Benzinga). MarketBeat’s consensus is “Strong Sell,” and TipRanks flags a “Downside potential” of ~30% (MarketBeat).
  • Profitability Still Out of Reach in 2025: OSCR is expected to operate at a loss—losses projected around $200–300 million for the year (Yahoo Finance). Its Q2 GAAP loss was $0.89/share, and medical loss ratio (MLR) swelled from 79% in 2024 to 91.1% in Q2 2025 (BenzingaStockAnalysis). These factors dampen bullish expectations.

Headlines-Style Article: “Oscar Health: Can It Make the Leap to $40 by Christmas 2025?”

New York, August 23, 2025 – Oscar Health Inc. (NYSE: OSCR) currently trades near $16.98, buoyed by stellar revenue growth, robust liquidity, and a landmark new partnership but Wall Street’s confidence remains tepid.

Why $40 isn’t implausible:

  • Long-term algorithmic forecasts place December 2025 prices in the low-$30s, including a possible high of $35.72 (StockScan).
  • Strengthened cash position of $4.86 billion, coupled with rising operating cash flows, enhances the company’s financial flexibility (Michael Burry’s Insights).
  • Innovative ventures like the Hy-Vee collaboration, targeting 400,000 employees, position Oscar to disrupt cost structures and tap new revenue streams (Benzinga).
  • A confirmed revenue guidance of $12–12.2 billion highlights strong underlying demand despite macro-healthcare headwinds (Yahoo FinanceStockAnalysis).

But hurdles remain:

  • Analyst targets remain pessimistic, ranging mostly between $8 and $14, with an average nearer $11–12 (ZacksThe Wall Street JournalPriceTargetsInvesting.com).
  • Profitability is still elusive: projected operational losses of up to $300 million in 2025, and increased medical loss ratios (MLR) eroding margins (BenzingaYahoo FinanceStockAnalysis).
  • Sentiment skews negative, with ratings from “Hold” to “Strong Sell” prevailing, reflecting elevated policy-related and insurance-market risks (MarketBeat).

Final Thoughts: While consensus targets place Oscar Health under $15, a confluence of strong cash reserves, growth initiatives, and bullish long-term models could propel the stock into the low $30s by Christmas-though doing so would require sustained execution and favorable market sentiment in the face of continued near-term challenges.

Disclaimer: The author holds a position in $OSCR Oscar Healthcare and this article should not be considered financial advice. Always conduct your own research before making any investment decisions.

References

Benzinga. (2025, August 20). Oscar Health faces analyst questions on path to profitability. Benzinga. https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/08/47133490/oscar-health-faces-analyst-questions-on-path-to-profitability

Benzinga. (2025, August 21). What’s going on with Oscar Health stock on Wednesday? Benzinga. https://www.benzinga.com/news/health-care/25/08/47240234/whats-going-on-with-oscar-health-stock-on-wednesday

Finance Yahoo. (2025, August 19). Oscar Health (OSCR) updates 2025 revenue guidance. Yahoo! Finance. https://finance.yahoo.com/news/oscar-health-oscr-updates-2025-174216635.html

MarketBeat. (2025). Oscar Health analyst ratings and price targets. MarketBeat. https://www.marketbeat.com/stocks/NYSE/OSCR/

Michael-Burry.com. (2025, August). Oscar Health stock analysis. Michael-Burry.com. https://www.michael-burry.com/oscr-stock-analysis/

Seeking Alpha. (2025, July 30). Oscar Health stock: Undervalued, but not without risk. Seeking Alpha. https://seekingalpha.com/article/4814520-oscar-health-stock-undervalued-but-not-without-risk

Stockanalysis.com. (2025). Oscar Health (OSCR) financials and stock data. Stock Analysis. https://stockanalysis.com/stocks/oscr/

Stockscan.io. (2025). Oscar Health stock forecast. StockScan. https://stockscan.io/stocks/OSCR/forecast

StockStory.org. (2025). Oscar Health stock insights. StockStory. https://stockstory.org/us/stocks/nyse/oscr

The Wall Street Journal. (2025). Oscar Health Inc. research ratings & reports. WSJ. https://www.wsj.com/market-data/quotes/OSCR/research-ratings

Zacks Investment Research. (2025). Oscar Health (OSCR) price targets & forecasts. Zacks. https://www.zacks.com/stock/research/OSCR/price-target-stock-forecast